- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07581470
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Trial Evaluating Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Effective pain control after total hip arthroplasty (THA) remains a key component of perioperative care, as inadequate analgesia may delay mobilization, prolong hospital stay, and increase the need for opioids. Regional anesthesia techniques, such as the pericapsular nerve group (PENG) block, are increasingly used to improve postoperative pain management while preserving motor function.
Dexamethasone administered intravenously is commonly used in perioperative care, primarily for the prevention of postoperative nausea and vomiting. In addition, it has been shown to prolong the duration of analgesia when used as an adjunct to regional anesthesia. However, there is still uncertainty regarding the optimal intravenous dose that provides clinically meaningful analgesic benefit without increasing the risk of adverse effects, particularly hyperglycemia.
Previous studies have typically used doses ranging from 4 mg to 8 mg, but direct comparisons between these doses, as well as comparison with placebo, remain limited in patients undergoing THA. Furthermore, the potential dose-response relationship of intravenous dexamethasone in this specific surgical population has not been clearly established.
This study is designed to address this knowledge gap by evaluating whether intravenous dexamethasone provides additional analgesic benefit in patients undergoing THA with PENG block, and whether higher doses result in improved outcomes compared to lower doses or no dexamethasone. The findings may help optimize perioperative analgesic strategies and support more evidence-based dosing of dexamethasone in orthopedic surgery.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Małgorzata Reysner, MD PhD
- Numéro de téléphone: +48 (61) 8310122
- E-mail: mreysner@ump.edu.pl
Sauvegarde des contacts de l'étude
- Nom: Tomasz Reysner, MD PhD
- Numéro de téléphone: +48 (61) 8310122
- E-mail: mreysner@ump.edu.pl
Lieux d'étude
-
-
-
Poznan, Pologne, 62-701
- Recrutement
- Poznan University of Medical Sciences
-
Contact:
- Malgorzata Reysner, M.D. Ph.D.
- Numéro de téléphone: +48 61 873 83 03
- E-mail: mreysner@ump.edu.pl
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years
- Scheduled for elective total hip arthroplasty (THA)
- Planned use of regional anesthesia including PENG block
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to understand the study procedures and provide written informed consent
- Ability to assess pain using the Numeric Rating Scale (NRS)
Exclusion Criteria:
- Known hypersensitivity to dexamethasone or any component of the study medication
- Chronic corticosteroid therapy or use of systemic steroids within 14 days prior to surgery
- Active systemic infection or sepsis
- Significant immunosuppression (e.g., chemotherapy, biological therapy)
- Pregnancy or breastfeeding
- Severe cognitive impairment or inability to reliably assess pain
- Uncontrolled diabetes mellitus (e.g., HbA1c > 8.5% or baseline blood glucose > 200 mg/dL)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo (0 mg Intravenous Dexamethasone)
Participants receive placebo (0.9% sodium chloride) administered intravenously in a volume identical to active treatment after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous administration of 0.9% sodium chloride in a volume identical to active treatment, given after induction of anesthesia.
Autres noms:
|
|
Comparateur actif: Dexamethasone 4 mg Intravenous
Participants receive 4 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 4 mg
Autres noms:
|
|
Comparateur actif: Dexamethasone 8 mg Intravenous
Participants receive 8 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 8 mg
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to First Rescue Analgesia
Délai: 48 hours after surgery
|
Time from the end of surgery to the first administration of rescue analgesia (opioid) due to inadequate pain control (Numeric Rating Scale ≥ 4 or patient request). |
48 hours after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain Intensity
Délai: 6 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
6 hours after surgery
|
|
Postoperative Pain Intensity
Délai: 12 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
12 hours after surgery
|
|
Postoperative Pain Intensity
Délai: 24 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
24 hours after surgery
|
|
Postoperative Pain Intensity
Délai: 48 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
48 hours after surgery
|
|
Opioid Consumption
Délai: 48 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
48 hours after surgery
|
|
Opioid Consumption
Délai: 24 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
24 hours after surgery
|
|
Incidence of Postoperative Nausea and Vomiting (PONV)
Délai: 24 hours after surgery
|
Occurrence of nausea and/or vomiting and need for antiemetic treatment. |
24 hours after surgery
|
|
Blood Glucose Levels
Délai: immidietly after surgery (0 hours after surgery)
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
immidietly after surgery (0 hours after surgery)
|
|
Blood Glucose Levels
Délai: 6 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
6 hours after surgery
|
|
Blood Glucose Levels
Délai: 12 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
12 hours after surgery
|
|
Blood Glucose Levels
Délai: 24 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
24 hours after surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Justyna Marszałek-Buko, MD, Poznan University of Medical Sciences
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies musculo-squelettiques
- Arthrite
- Maladies articulaires
- Maladies rhumatismales
- Arthrose
- Arthrose, Hanche
- Composés polycycliques
- Produits chimiques inorganiques
- Composés de chlore
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Stéroïdes, fluorés
- Grossissement
- Composés de sodium
- Chlorures
- Acide chlorhydrique
- Dexaméthasone
- dexaméthasone 21-phosphate
- Chlorure de sodium
Autres numéros d'identification d'étude
- 3/2026
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .